Topics:

Paclitaxel as Weekly One Hour Infusion Is Active in Metastatic Breast Cancer

Paclitaxel as Weekly One Hour Infusion Is Active in Metastatic Breast Cancer

NEW YORK—Paclitaxel (Taxol) given as a weekly one-hour infusion has significant activity in metastatic breast cancer and is well tolerated at a dose of 100 mg/m²/wk or less, researchers from Memorial Sloan-Kettering Cancer Center reported at a poster session of the San Antonio Breast Cancer Symposium.

In this phase II trial headed by Andrew Seidman, MD, eligible patients had received up to two prior chemotherapy regimens, but no previous taxane. The dose was modified every two to four weeks depending on toxicity. Since the researchers were also interested in paclitaxel pharmacology, assays were done at 0.5, 1, 3, 6, 25, and 26 hours.

A lack of cumulative neutropenia allowed paclitaxel dose escalation to 110 to 120 mg/m². However, since grade 3 peripheral neuropathy was seen in five of nine patients at these doses, no further escalations above 100 mg/m²/wk were done.

To date, one complete and five partial responses have been seen in 15 evaluable patients, for an objective response rate of 40%. Pharmacokinetic data in 14 patients revealed paclitaxel levels adequate for cytotoxicity.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.